Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11530213 Naphthyridinone derivatives and their use in the treatment of arrhythmia

Patent 11530213 was granted and assigned to Novartis on December, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Novartis

Current Assignee

Novartis

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11530213

Date of Patent

December 20, 2022

Patent Application Number

17071311

Date Filed

October 15, 2020

Patent Citations

‌

US Patent 10266551 Compounds and uses thereof for the modulation of hemoglobin

‌

US Patent 10844055 Naphthyridinone derivatives and their use in the treatment of arrhythmia

Patent Primary Examiner

CPC Code

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11530213 Naphthyridinone derivatives and their use in the treatment of arrhythmia

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API